PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
2539902-1	1989	Our human T-cell leukemia line, CEM/VM-1, selected for resistance to VM-26 (teniposide), is cross-resistant to several drugs that interact with topoisomerase II, including VP-16 (etoposide), 4"-(9-acridinylamino)methanesulphon-m-anisidide, daunorubicin, and mitoxantrone.	Daunorubicin	240-252	host cell factor C1	Homo sapiens	172-177	
2564628-10	1989	In contrast, daunorubicin increased VP-16 accumulation only in the sensitive MCF-7 cell line, whereas the efflux rate of VP-16 was not significantly changed in either cell line.	Daunorubicin	13-25	host cell factor C1	Homo sapiens	36-41	
7808368-9	1994	In leukemias we administered vincristine (1.5 mg/m2), and daunomycin (40 mg/m2), in solid tumors VP16 (150 mg/m2) and adriamycin (60 mg/m2).	Daunorubicin	58-68	host cell factor C1	Homo sapiens	97-101	
291472-2	1979	In the first patient (a 7-month-old female with acute monocytic leukemia) extremely young age and previous chemotherapy with a podophyllotoxin derivative, VP-16, may have prediposed the patient to fatal congestive heart failure at a total Daunorubicin dose of only 225 mg/m2.	Daunorubicin	239-251	host cell factor C1	Homo sapiens	155-160	
10708946-4	2000	In our study, we examined the effects of buthionine sulphoximine (BSO), an inhibitor of GSH biosynthesis, on the nuclear accumulation of daunorubicin (DNR), in etoposide (VP16) and doxorubicin (ADR) resistant MCF7 cell lines, overexpressing respectively MRP1 (MCF7/VP) and Pgp (MCF7/ADR).	Daunorubicin	137-149	host cell factor C1	Homo sapiens	171-175